Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rucaparib - Clovis Oncology

Drug Profile

Rucaparib - Clovis Oncology

Alternative Names: AG-014699; AG-14699; CO-338; PF-01367338; PF-1367338; Rubraca; Rucaparib phosphate

Latest Information Update: 06 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cancer Research UK
  • Developer Bristol-Myers Squibb; Cancer Research UK; Clovis Oncology; Merck Sharp & Dohme; NHS Greater Glasgow and Clyde; Roche; UNICANCER; University of Colorado at Denver; University of Oklahoma; University of Utah
  • Class 3-ring heterocyclic compounds; Antineoplastics; Azepines; Indoles; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase 1 inhibitors; Poly(ADP-ribose) polymerase 2 inhibitors; Poly(ADP-ribose) polymerase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer
  • Phase II Breast cancer; Cervical cancer; Endometrial cancer; Gastric cancer; Mesothelioma; Pancreatic cancer; Solid tumours; Urogenital cancer
  • Phase I/II Non-small cell lung cancer
  • Phase I Gynaecological cancer
  • Suspended Malignant melanoma

Most Recent Events

  • 04 Oct 2021 Biomarkers information updated
  • 25 Aug 2021 Launched for Ovarian cancer in Netherlands, prior to August 2021 (PO)
  • 24 Aug 2021 Registered for Ovarian cancer (Recurrent, Second-line therapy or greater) in Switzerland (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top